# 2026-04253: FDA Releases New Guidance on Real-World Drug Safety Studies

2026-04253, M14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-Interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines; International Council for Harmonisation; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-04, effective 2026-03-04; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04253
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04253
- Title: M14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-Interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines; International Council for Harmonisation; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 10615
- Published: 2026-03-04
- Effective: 2026-03-04
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Releases New Guidance on Real-World Drug Safety Studies

## Summary

The FDA just released new rules to help drug makers and researchers use real-world data to check medicine safety better and faster. This update affects anyone doing non-interventional studies on drugs, vaccines, or biologics, replacing older guidance and aiming to make safety checks smoother without extra costs. The new guidance is effective now and encourages clear planning, smart data use, and honest reporting to keep medicines safe for everyone.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "General Principles on Planning, Designing, Analyzing, and Reporting of Non- interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines." The guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The guidance outlines general principles on planning, designing, analyzing, and reporting non-interventional studies that utilize real-world data for safety assessment of medicines (i.e., drugs, vaccines, and other biological products). The recommendations in this guidance, while focused on safety, are applicable to non-interventional studies assessing effectiveness and are aligned and complementary with the FDA's other guidances on the generation real world evidence. The guidance includes recommendations and high-level best practices for the conduct of these studies, including articulating the research question, selecting appropriate data sources, defining key variables, addressing potential biases and confounding, conducting analyses, reporting, and submission. The guidance is intended to streamline the development and regulatory assessment of postmarketing non-interventional safety studies that include real-world data. The guidance replaces the draft guidance "M14 General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines" issued in July 2024. FDA is also announcing the withdrawal of the guidance entitled "Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets," published May 2013.

## Effects PRIA read

- Final M14 Guidance Available: benefit, medium. The FDA issued the final ICH M14 guidance on March 4, 2026 for non-interventional studies that use real-world data to assess the safety of medicines (drugs, vaccines, and biological products). The guidance lays out recommended principles for planning, designing, analyzing, reporting, and submitting…
- Older Guidance Withdrawn and Draft Finalized: benefit, low. The final M14 guidance finalizes the July 5, 2024 draft and, upon publication, FDA intends to withdraw the prior guidance titled "Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data" published May 14, 2013. The final guideline was endors…
- No New Paperwork Burden: benefit, low. The guidance contains no new collection of information under the Paperwork Reduction Act, and it references previously approved FDA information collections (for example, OMB control numbers 0910-0014, 0910-0001, and others).
- Enhanced Methodology and Reporting Guidance: benefit, medium. The final guidance includes comprehensive recommendations and enhanced discussion on Initial Design and Feasibility, the Conceptual Framework, quantitative bias analysis, and protocol development including characteristics and types of data sources. These revisions followed public comment and were i…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04253 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/04/2026-04253/m14-general-principles-on-planning-designing-analyzing-and-reporting-of-non-interventional-studies)
- [2026-04253 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-04/pdf/2026-04253.pdf)

## Related
- [Previous: 2026-04252, E2D(R1) Postapproval Safety Data: Definitions and Standards for Management and…](https://policyrisk.com/federal-register/2026-04252)
- [Next: 2026-04255, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Co…](https://policyrisk.com/federal-register/2026-04255)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04253 (as of 2026-06-08).
